Dizal Leads China's Biotech Innovation by Showcasing Strength of its Oncology Pipeline at 2023 ASCO
- Written by PR Newswire
 |
- Two highly anticipated oral presentations captured attention: first pivotal study of sunvozertinib (WU-KONG6) and multinational pivotal study of golidocitinib (JACKPOT8)
- Sunvozertinib achieved an ORR of 60.8% in ≥ second-line treatment and 77.8% in the first-line treatment for EGFR Exon20ins NSCLC
- Sunvozertinib demonstrated durable benefit in...
